Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 4/20 | 0.66 |
| ▸ | EGFR | P00533 | 3/20 | 0.54 |
| ▸ | ERBB3 | P21860 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25387375 | 0.90 | KMO (0.54) | KMOEGFRERBB3MEN1KMT2A | |
| SCHEMBL3221134 | 0.87 | KMO (0.67) | KMOEGFRERBB3MEN1KMT2A | |
| SCHEMBL13472427 | 0.87 | KMO (0.62) | KMOEGFRERBB3MEN1KMT2A | |
| SCHEMBL3226154 | 0.85 | S1PR1 (0.61) | KMOEGFRERBB3MEN1KMT2A | |
| SCHEMBL21645363 | 0.85 | KMO (0.65) | KMOEGFRERBB3MEN1KMT2A | |
| SCHEMBL3225993 | 0.84 | MEN1 (0.57) | KMOEGFRERBB3MEN1KMT2A | |
| SCHEMBL13472426 | 0.82 | KMO (0.54) | KMOMEN1KMT2ANPC1RAB9A | |
| SCHEMBL414719 | 0.81 | MEN1 (0.70) | EGFRERBB3MEN1KMT2ANPC1 | |
| SCHEMBL3221150 | 0.79 | S1PR1 (0.58) | KMOEGFRERBB3MEN1KMT2A | |
| SCHEMBL3231476 | 0.79 | MAPT (0.61) | EGFRERBB3MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240336593-A1 | Compound Having Antitumor Activity And Use Thereof | INNOVSTONE THERAPEUTICS LIMITED (CN) | 2024-10-10 | — | — | US | disclosed |
| EP-4209485-A1 | COMPOUND HAVING ANTITUMOR ACTIVITY AND USE THEREOF | Innovstone Therapeutics Limited (CN) | 2023-07-12 | — | — | EP | disclosed |
| EP-4209485-A1 | COMPOUND HAVING ANTITUMOR ACTIVITY AND USE THEREOF | Innovstone Therapeutics Limited (CN) | 2023-07-12 | — | — | EP | disclosed |
| CN-116113626-A | Compound with anti-tumor activity and application thereof | 上海翊石医药科技有限公司 | 2023-05-12 | — | — | CN | disclosed |
| WO-2022048631-A1 | COMPOUND HAVING ANTITUMOR ACTIVITY AND USE THEREOF | 上海翊石医药科技有限公司 | 2022-03-10 | — | — | WO | disclosed |
| WO-2010020432-A8 | COMPOUNDS FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | BIOMARIN IGA LIMITED (BS) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010020432-A2 | COMPOUNDS FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336593-A1 | Compound Having Antitumor Activity And Use Thereof | PRMT5, PRMT1, PRMT6 | KMO 951/4885EGFR 3478/4885ERBB3 2738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.